Myomo Inc. unveils presentation highlighting wearable robotics for upper limb paralysis and Medicare reimbursement expansion

Reuters

2025/11/19

<a href="https://laohu8.com/S/MYO">Myomo Inc.</a> unveils presentation highlighting wearable robotics for upper limb paralysis and Medicare reimbursement expansion

Myomo Inc. has released a new investor presentation outlining its strategic positioning in the wearable medical robotics market. The company highlights the MyoPro myoelectric orthosis as a first-mover in addressing upper limb paralysis caused by conditions such as stroke, nerve injury, and neurological diseases. The presentation details recent developments in insurance reimbursement, including expanded access through Medicare Part B and approvals from health insurance providers in Germany and Australia. Myomo also discusses its direct provider business and new distribution channels, noting that Medicare Advantage plans are now required to follow Medicare coverage guidelines. Updated reimbursement rates for the MyoPro under HCPCS codes L8701 and L8702 are included, with effective fees set for January 2025. The company identifies a substantial market opportunity due to an expanded addressable population and ongoing global reimbursement efforts. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myomo Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584541009"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584541009\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584541009?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 00:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584541009","market":"us","top_or_hot":-1,"title":"Myomo Inc. unveils presentation highlighting wearable robotics for upper limb paralysis and Medicare reimbursement expansion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MYO\">Myomo Inc.</a> unveils presentation highlighting wearable robotics for upper limb paralysis and Medicare reimbursement expansion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Myomo Inc. has released a new investor presentation outlining its strategic positioning in the wearable medical robotics market. The company highlights the MyoPro myoelectric orthosis as a first-mover in addressing upper limb paralysis caused by conditions such as stroke, nerve injury, and neurological diseases. The presentation details recent developments in insurance reimbursement, including expanded access through Medicare Part B and approvals from health insurance providers in Germany and Australia. Myomo also discusses its direct provider business and new distribution channels, noting that Medicare Advantage plans are now required to follow Medicare coverage guidelines. Updated reimbursement rates for the MyoPro under HCPCS codes L8701 and L8702 are included, with effective fees set for January 2025. The company identifies a substantial market opportunity due to an expanded addressable population and ongoing global reimbursement efforts. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myomo Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myomo Inc. unveils presentation highlighting wearable robotics for upper limb paralysis and Medicare reimbursement expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyomo Inc. unveils presentation highlighting wearable robotics for upper limb paralysis and Medicare reimbursement expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 00:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MYO\">Myomo Inc.</a> unveils presentation highlighting wearable robotics for upper limb paralysis and Medicare reimbursement expansion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Myomo Inc. has released a new investor presentation outlining its strategic positioning in the wearable medical robotics market. The company highlights the MyoPro myoelectric orthosis as a first-mover in addressing upper limb paralysis caused by conditions such as stroke, nerve injury, and neurological diseases. The presentation details recent developments in insurance reimbursement, including expanded access through Medicare Part B and approvals from health insurance providers in Germany and Australia. Myomo also discusses its direct provider business and new distribution channels, noting that Medicare Advantage plans are now required to follow Medicare coverage guidelines. Updated reimbursement rates for the MyoPro under HCPCS codes L8701 and L8702 are included, with effective fees set for January 2025. The company identifies a substantial market opportunity due to an expanded addressable population and ongoing global reimbursement efforts. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myomo Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYO","symbol_name":"Myomo Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL4lzkXq:1","article_id":"2584541009","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584541009","pubTimestamp":1763485104,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Myomo Inc. has released a new investor presentation outlining its strategic positioning in the wearable medical robotics market. The company highlights the MyoPro myoelectric orthosis as a first-mover in addressing upper limb paralysis caused by conditions such as stroke, nerve injury, and neurological diseases. The presentation details recent developments in insurance reimbursement, including expanded access through Medicare Part B and approvals from health insurance providers in Germany and Australia. Myomo also discusses its direct provider business and new distribution channels, noting that Medicare Advantage plans are now required to follow Medicare coverage guidelines. Updated reimbursement rates for the MyoPro under HCPCS codes L8701 and L8702 are included, with effective fees set for January 2025. The company identifies a substantial market opportunity due to an expanded addressable population and ongoing global reimbursement efforts. You can access the full presentation throug","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYO":"Myomo Inc.","BK4082":"医疗保健设备"},"translate_title":"Myomo Inc.推出演示文稿，重点介绍可穿戴机器人治疗上肢瘫痪和医疗保险报销扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYO":0.9},"content_text":"Myomo Inc. unveils presentation highlighting wearable robotics for upper limb paralysis and Medicare reimbursement expansion\n    \n\n        Myomo Inc. has released a new investor presentation outlining its strategic positioning in the wearable medical robotics market. The company highlights the MyoPro myoelectric orthosis as a first-mover in addressing upper limb paralysis caused by conditions such as stroke, nerve injury, and neurological diseases. The presentation details recent developments in insurance reimbursement, including expanded access through Medicare Part B and approvals from health insurance providers in Germany and Australia. Myomo also discusses its direct provider business and new distribution channels, noting that Medicare Advantage plans are now required to follow Medicare coverage guidelines. Updated reimbursement rates for the MyoPro under HCPCS codes L8701 and L8702 are included, with effective fees set for January 2025. The company identifies a substantial market opportunity due to an expanded addressable population and ongoing global reimbursement efforts. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myomo Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}